Overuse of Acid-Suppression Therapy at an Urban Tertiary Hospital

Southern Medical Journal

Volumn 108, Issue 12, 2015, Pages 732-738

  Redfern, Roberta E ^a,b,c   Brown, Megan ^a,b,c   Karhoff, Kathryn L ^a,b,c   Middleton, Jennifer L ^a,b,c  

^a RIVERSIDE METHODIST HOSPITAL   (United States)

^b ProMedica   (Spain)

^c Eastern Woods Family Practice   (United States)

Author keywords

clinical practice guidelines; histamine H2 antagonists; nonsteroidal anti inflammatory drugs; prescribing patterns; proton pump inhibitors

Indexed keywords

ANTIULCER AGENT; BICARBONATE PLUS OMEPRAZOLE; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; LANSOPRAZOLE; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; RABEPRAZOLE; RANITIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

ACID SUPPRESSIVE THERAPY; ADULT; AGE; ARTICLE; CHARLSON COMORBIDITY INDEX; DISEASE ASSOCIATION; DRUG ABUSE; DRUG INDICATION; FEMALE; HIGH RISK PATIENT; HUMAN; INAPPROPRIATE PRESCRIBING; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL RECORD REVIEW; MIDDLE AGED; PRESCRIPTION; PROPHYLAXIS; PROTOCOL COMPLIANCE; SEX DIFFERENCE; STRESS ULCER; TERTIARY CARE CENTER; TREATMENT WITHDRAWAL; ULCER; AGED; HOSPITAL; HOSPITALIZATION; PEPTIC ULCER; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-ULCER AGENTS; FEMALE; HISTAMINE H2 ANTAGONISTS; HOSPITALIZATION; HOSPITALS, URBAN; HUMANS; INAPPROPRIATE PRESCRIBING; MALE; MIDDLE AGED; PEPTIC ULCER; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84949227261     PISSN: 00384348     EISSN: 15418243     Source Type: Journal    
DOI: 10.14423/SMJ.0000000000000383     Document Type: Article

References (29)

1. Guda NM, Noonan M, Kreiner MJ, et al. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol 2004;99:1233-1237.
2. Eid SM, Boueiz A, Paranji S, et al. Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists. Intern Med 2010;49:2561-2568.
3. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008;64:935-951.
4. Chen TJ, Chou LF, Hwang SJ. Trends in prescribing proton pump inhibitors in Taiwan: 1997-2000. Int J Clin Pharmacol Ther 2003;41:207Y212.
5. Mat Saad AZ, CollinsN, Lobo MM, et al. Proton pump inhibitors: A survey of prescribing in an Irish general hospital. Int J Clin Pract 2005;59:31-34.
6. Gupta R, Garg P, Kottoor R, et al. Overuse of acid suppression therapy in hospitalized patients. South Med J 2010;103:207-211.
7. Nardino RJ, Vender RJ, Herbert PN. Overuse of acid-suppressive therapy in hospitalized patients. Am J Gastroenterol 2000;95:3118-3122.
8. ASHP Therapeutic Guidelines on Stress Ulcer Prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. Am J Health Syst Pharm 1999;56:347-379.
9. Heidelbaugh JJ, Inadomi JM. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006;101:2200-2205.
10. Hussain S, Stefan M, Visintainer P, et al. Why do physicians prescribe stress ulcer prophylaxis to general medicine patients? South Med J 2010;103:1103-1110.
11. Bez C, Perrottet N, Zingg T, et al. Stress ulcer prophylaxis in non-critically ill patients: A prospective evaluation of current practice in a general surgery department. J Eval Clin Pract 2013;19:374-378.
12. Lopez-Doriga Bonnardeaux P, Neira Alvarez M, Mansilla Laguia S. Proton bomb inhibitors: A study of the prescription in a functional recovery unit. Rev Esp Geriatr Gerontol 2013;48:269-271.
13. Reid M, Keniston A, Heller JC, et al. Inappropriate prescribing of proton pump inhibitors in hospitalized patients. J Hosp Med 2012;7:421-425.
14. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol 2010;5:288-297.
15. Leri F, Ayzenberg M, Voyce SJ, et al. Four-year trends of inappropriate proton pump inhibitor use after hospital discharge. South Med J 2013; 106:270-273.
16. Thomas L, Culley EJ, Gladowski P, et al. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010;16:122-129.
17. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, et al. Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003;18:847-851.
18. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006;24:613-619.
19. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003;54:243-245.
20. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296:2947-2953.
21. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2008;27:1110-1121.
22. de Jager CP, Wever PC, Gemen EF, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. Aliment Pharmacol Ther 2012;36:941-949.
23. Chan FK. Primer:managing NSAID-induced ulcer complicationsVbalancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 2006;3:563-573.
24. Lanza FL, Chan FK, Quigley EM, et al. Guidelines for prevention of NSAID-related ulcer complications.AmJGastroenterol 2009;104:728-738.
25. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev 2002;4:CD002296.
26. Issa IA, Soubra O, Nakkash H, et al. Variables associated with stress ulcer prophylaxis misuse: A retrospective analysis. Dig Dis Sci 2012;57:2633-2641.
27. Hoover JG, Schumaker AL, Franklin KJ. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci 2009;54:1947-1952.
28. Grant K, Al-Adhami N, Tordoff J, et al. Continuation of proton pump inhibitors from hospital to community. Pharm World Sci 2006;28:189-193.
29. Masica AL, Richter KM, Convery P, et al. Linking joint commission inpatient core measures and national patient safety goals with evidence. Proc Baylor Univ Med Cent 2009;22:103-111.